珍寶島(603567.SH):斥4億元投資特瑞思進軍生物藥領域
格隆匯6月15日丨珍寶島(603567.SH)公吿,公司擬與公司持股5%以上股東虎林龍鵬投資中心(有限合夥)(“龍鵬投資”)共同投資浙江特瑞思藥業股份有限公司(“特瑞思”或“標的公司”),其中珍寶島投資人民幣4億元,佔特瑞思增資擴股後總股本的16.6665%;龍鵬投資將其對特瑞思享有的約6.20億元債權轉換為股權,約佔特瑞思增資擴股後總股本的25.8429%。
特瑞思位於浙江省湖州市經濟技術開發區,研發和生產基地一期佔地面積150餘畝,擁有中國首家符合國際cGMP標準的大型商業化生物藥生產基地,突破了中國單抗藥物工藝放大、大規模生產的技術瓶頸,具有成本優勢,同時還為國內和國際的合作伙伴提供CDMO服務,為企業提供高效、靈活的解決方案。
此次認購特瑞思增發股份,進軍生物藥領域,是珍寶島戰略轉型和國際化接軌的重要舉措,有利於增強公司的核心競爭力,為公司未來發展奠定良好基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.